key: cord-0877751-aabjus3b
authors: Tsakiri, Maria; Naziris, Nikolaos; Demetzos, Costas
title: Innovative vaccine platforms against infectious diseases: under the scope of the COVID-19 pandemic
date: 2021-10-20
journal: Int J Pharm
DOI: 10.1016/j.ijpharm.2021.121212
sha: 9def73d82c3b7ab47c56b239edc133ee6439387a
doc_id: 877751
cord_uid: aabjus3b

While classic vaccines have proved greatly efficacious in eliminating serious infectious diseases, innovative vaccine platforms open a new pathway to overcome dangerous pandemics via the development of safe and effective formulations. Such platforms play a key role either as antigen delivery systems or as immune-stimulators that induce both innate and adaptive immune responses. Liposomes or lipid nanoparticles, virus-like particles, nano-emulsions, polymeric or inorganic nanoparticles, as well as viral vectors, all belong in the nanoscale and are the main categories of innovative vaccines that are currently on the market or in clinical and pre-clinical phases. In this paper, we review the above formulations used in vaccinology and we discuss their connection with the development of safe and effective prophylactic vaccines against SARS-CoV-2.

40 COVID-19 outbreak, caused by the virus SARS-CoV-2, proved that a single nano-sized virus can cause intense unrest worldwide, with serious consequences for modern societies (Bedford et al., 2019; Rauch et al., 2018) . Lockdowns and personal prophylactic measures played a key role in controlling the transmissibility of the virus. However, more direct solutions for the elimination of a pandemic are necessary. 45 Although effective, catholic lockdowns are too aggressive for the economy and mental public health, while personal hygiene and prophylactic measures depend on the individual's responsibility. Effective vaccines remain on top priority for handling epidemics those situations. Vaccination was first performed by Edward Jenner (1796) (Stern and Markel, 2005) 50 and vaccines were advanced by Louis Pasteur (Baxby, 1999) . Nowadays, we can classify vaccines in three main generations. The first generation contains the liveattenuated or inactivated vaccines of pathogens. Several efficacious vaccines of this type have been produced against smallpox (WHO, 2004) , tuberculosis (Covián et al., 2019) , poliomyelitis (Kew et al., 2005) and the seasonal or the pandemic flu (Herold 55 and Sander, 2020) . Indeed, smallpox was eradicated in the 1980s and poliomyelitis is nearly eradicated today (Minor, 2015) . Subunit (second-generation) vaccines contain only specific immunogenic domains of the pathogen. Domains that are usually used are the membrane, capsid proteins or toxins (Torii et al., 2017) of germs and viruses (Morein and Simons, 1985) . Sometimes, the pathogenic proteins have the ability to self-60 assemble into particulate systems, known as virus-like particles (VLPs) (Noad and Roy, 2003) . Subunit vaccines seem to have a better safety profile than live-attenuated or inactivated vaccines. However, they are less immunogenic, resulting in weaker and sometimes insufficient response. Thus, the majority of these vaccines require an immunomodulator, i.e., an adjuvant, to induce an immune response (Cimica and 65 Galarza, 2017) . Some of the most widely used vaccines nowadays belong in this category, such as human papillomavirus and hepatitis B vaccines Yadav et al., 2019) . Third-generation vaccines do not contain antigenic proteins of pathogens, but part of their genetic material. Such vaccines have recently been approved for human use 70 (EMA, 2020a; Kim et al., 2020) and the expectation is that they will bring a revolution in the field of vaccinology. The genetic material is encapsulated into nanoparticles and transferred inside the target host cells. When released, the genetic material, DNA or RNA, is expressed by the host, as in the case of an infection. Hence, an accurate architecture of the expressed antigenic protein is produced. The cost of production for 75 nucleic acid vaccines is one of their main advantages, as the manufacturing process is simpler and has higher repeatability in comparison with previous generation vaccines (Lee et al., 2018; Tejeda-Mansir et al., 2019) . On the other hand, when DNA is the cargo, it must pass into the nucleus to produce the intermediate mRNA molecule that will be then translated into the immunogenic protein. mRNA vaccines need only to 80 pass the plasma membrane, which is easier than passing the nuclei membrane. The mRNA molecules have a dual role in the stimulation of the immune system. First, they are the templates for the formation of the desired antigenic protein and secondly, they can act as adjuvants that are recognized by endosomal and cytosolic innate immune receptors, such as Toll-like receptors 3,7 and 8 (Rauch et al., 2018) . Despite their 85 important advantages, nucleic acid vaccines have not been evaluated for a long period and a certain degree of doubt about their mechanism of action still exists. For example, the exogenous plasmid DNA that is inserted into the nucleus might remain there for a longer time period than intended, leading to worries for genomic integration and mutagenesis (Rauch et al., 2018) . As many DNA-based vaccines utilize stable plasmids 90 for the transfer of the desirable genes and not a platform or a vector, here we emphasize on mRNA vaccines. At this point, it is important to note that many of the aforementioned innovative technologies follow the physicochemical principles of nanotechnology. In the last decades, nanomedicine has boosted progress and some impressive results have been 95 achieved in its short-term history. In vaccinology, nanoparticles have a dual role, as their action includes both antigen delivery and adjuvanticity. Functional platforms, consisting of stimuli-responsive biomaterials that can be administrated by alternative routes result in decrease of the cost, time and effort needed for the design and development of effective vaccines. Nano-vaccinology allowed the development of a 100 smart-vaccine against COVID-19 in less than a year.

The two arms of human immunity are equally important for the protection against infections and cellular malfunctions, producing an enhanced humoral and cellular 105 cascade. Innate response contains all the non-specialized mechanisms of protection.

The complement inactivates foreign factors, while granulocytes produce high amounts of chemokines and cytokines (Falcone et al., 2001; Jiao et al., 2016; Voehringer, 2009; Zipfel and Skerka, 2009) . Innate antigen presenting cells (APCs) phagocytose the pathogens and present antigenic epitopes via their major histocompatibility complexes 110 (MHC) I and II (Delamarre and Mellman, 2011; Mellman, 2013) . The recognition of antigens occurs in the pathogen recognition receptors (PRRs) of APCs. Finally, natural killer lymphocytes detect infected host, allogenic, or cancer cells and cytolyze them (Cerwenka and Lanier, 2016; Hammer et al., 2018) . After the activation of the innate response, the APCs, mostly the dendritic cells, migrate from the peripheral tissues to 115 the lymph nodes. In the lymph nodes, they present antigens to the cells of adaptive immunity. T-cells are responsible for the cellular induction, while B-cells produce high quantities of specialized antibodies that neutralize and signal the antigens. CD8 + Tcells, also called cytotoxic T-cells, recognize antigens presented in MHC I and CD4 + T-cells or T-helper cells (T H ) are activated by antigens into MHC II (Kräutler et al., 120 2017; Leung et al., 2010; Schudel et al., 2019) . Both classes of adaptive lymphocytes produce immunity memory and are able to provide long-lasting protection against the same or even very similar antigens (cross-protection) (Jameson and Masopust, 2018; Kurosaki et al., 2015; Netea et al., 2019) .

125 2.1 Innate Immunity When a pathogen or antigen is presented into a tissue or in body fluids the innate response is immediately activated. The Complement, granulocytes, macrophages, and dendritic cells promote the release of a plethora of active molecules, including chemokines, cytokines, interferons, and complement components. Firstly, complement 130 activation leads to the opsonization or lysis of the antigen membrane via three routes: the classical, the alternative and the mannan-binding lectin pathway (Zipfel and Skerka, 2009) . Furthermore, neutrophils are granulocytes that normally flow in the blood and can recognize signals from infected cells and macrophages. After recognition, neutrophils gather in the site of the infection and phagocytose the antigens, while 135 simultaneously producing chemokines and other chemoattractants, leading to a further activation of the immune response. Eosinophils and basophils are other granulocytes in the bloodstream but they exist in much lower concentrations, compared with neutrophils. These two types of leucocytes have an important role in hypersensitivity responses and anti-parasite immunity (Falcone et al., 2001; Jiao et al., 2016; 140 Voehringer, 2009) .

Tissues also have their own immune cells. Immature dendritic cells and macrophages are located in peripheric tissues and in the presence of a pathogen, they have the ability of phagocytosis. The main difference between these two cell types of the innate system is that dendritic cells do not only phagocytose the pathogens but are also capable of 145 antigen presentation, in contrast with macrophages. The presentation occurs via binding of the antigen with major histocompatibility complex class I or II (MHC I or II). MHC class II is associated with the presentation of extracellular peptides derived from allergens, bacteria, protozoa, or dead host cells, while MHC class I is used for the presentation of intracellular proteins, such as viral proteins expressed by infected cells. 150 MHC I can be expressed by almost all nucleated cells while, MHC II is a privilege presentation complex of only professional antigen-presenting cells (Delamarre and Mellman, 2011; Mellman, 2013) . Phagocytic cells interact with the pathogens via recognition of the pathogen-associated molecular patterns (PAMPs) or dangerassociated molecular patterns (DAMPs) by their pathogen recognition receptors 155 (PRRs).

Lastly, natural killer cells (NK) are lymphocytes that detect infected host cells, allogenic cells, or cancer cells and cytolyze them. NK sense inflammatory signals such lasting B-cells (Kurosaki et al., 2015) . In contrast with memory B-cells, which induce prophylaxis through humoral memory, T-cells can also induce memory. Central 210 memory T-cells (T CM ) trafficking through lymphoid tissues, whereas effector memory  T-cells (T EM ) can accumulate other tissues. Thus, T CM and T EM can provide the functionalities of mature T-cells in the case of reinfection (Jameson and Masopust, 2018) .

Many innovative vaccines take advantage of the use of particulate antigen delivery systems and nano-adjuvants. Such "smart" platforms provide protection of the antigen from biological degradation, targeted delivery to the desirable cells after administration and higher immunogenicity. Below, we classify and analyze the most commonly used 220 vaccine platforms. Table 1 presents the vaccines that utilize nanoscale vaccine platforms.

225 Virus-like particles (VLPs) are the most common vaccine nanoplatforms for both prophylactic and therapeutic purposes (Smith et al., 2013) . The first nanovaccine, which was authorized in 1986 for hepatitis B prophylaxis, is classified in VLP-based vaccines (Zhao et al., 2013) . Until today, authorized VLP vaccines against hepatitis B virus (HBV), hepatitis E virus (HEV), and Human papilloma virus (HPV) are globally used 230 and many others are in clinical trials . According to ClinicalTrials.gov prophylactic vaccines against Chikungunya, Encephalitis virus and Norovirus are currently under clinical evaluation. Most VLPs have a size of 20-100 nm and consist of pathogens' surface proteins, without the presence of genetic material ( Fig. 1A ) (Smith et al., 2013) . This is the main 235 difference between VLPs and viruses, which leads to the advantage that there is no danger of pathogen proliferation. In other words, VLPs combine the immunogenicity of the viruses, based on highly organized supramolecular structures, without their pathogenicity, leading to safe and effective vaccines . The proteins used must have the ability to self-assemble into functional and 240 immunogenic nanostructures, mainly with the use of an expression system, prokaryotic or eukaryotic cell line. Yeast, bacteria, insect, mammalian and plant cells have been utilized for this purpose (Balke and Zeltins, 2020; EMA, 2020b; Li et al., 2015; Qian et al., 2020; Shouval et al., 2015; Yusibov et al., 2002) . The above is achieved by the right conformational orientation of the antigenic epitopes in the VLP surface and thus, 245 the production of high titers of specialized neutralizing antibodies (nAbs). The structure is stabilized with many intra-or inter-molecular covalent or hydrophobic interactions. Amino acids, such as cysteine and lysine have an important role in this activity due to their physicochemical properties (Berthier et al., 2020; Li et al., 2016) . Moreover, equally important is the switching of hydrophobic and hydrophilic domains for the 250 creation of stable formulations (Berthier et al., 2020) . As in the case of virus capsids, the antigenic proteins of VLPs self-assemble into highly symmetrical and strict architectures, usually icosahedral and octahedral, with statistically preferable repeatability (Gilbert et al., 2005; Lu et al., 2020) . Even in cases of complex hybrid systems that consist of more than one protein, the final formations do not present high 255 lot-to-lot deviation , maybe because the information of the functional conformation is encrypted in the monomer structure. However, significantly important variations may be observed if the expression system change. For example, prokaryotic cell lines do not have the ability of post-translational processing that may result in a difference in glycosylation and quadruple structure of the VLPs (Mohsen et 260 al., 2017) . Such differences might lead to alteration of the immunogenic response of the vaccine receiver. Concerning the immunogenicity, VLPs have proved to activate both the innate and the adaptive response. Complement activation via the classical pathway occurs after the vaccination, resulting in opsonization of the VLPs (Gomes et al., 2017) . In this way, 265 the repetitive epitopes of VLPs are recognized by the Toll-like receptors and become more easily visible from the components of the cellular immune system, especially dendritic cells (Tagliamonte et al., 2017) . VLPs result in the stimulation of CD4 + Thelper cells -T H 1 and T H 2. Furthermore, because of their virus-like behavior, DCs cross-present the epitopes in MHC I, concluding in the activation of CD8 + T-cells and 270 a more intense immune response (Bachmann and Jennings, 2010) . Small particulate antigens (<200 nm), such as VLPs, have the ability to enter the lymphatic system without the need of APCs (Manolova et al., 2008) . This is extremely important as the cell-free antigenic VLPs can directly interact with the follicular B-cells in the secondary lymphoid organs (Bachmann and Jennings, 2010). The cross-linking interaction is 275 much stronger than the DC one, and result in a more effective activation of the immune response with a much lower quantity of antigens (Hong et al., 2018) . Currently, scientists design standardized VLP platforms. An interesting idea was presented by Garg et al. They achieved to synthesize a multivalent VLP-based prophylactic vaccine against four arthropod-borne viruses -Chikungunya, Japanese 280 encephalitis, Yellow fever and Zika virus. The VLPs are secreted by 293T stable cell lines and generate a high amount of nAbs for all viruses in mice experiments. Such an approach is preferable for both manufactures and populations sensitive to these viruses, as it is a more economic technology than the production of live attenuated virus (LAV) vaccines and can protect against four viruses, minimizing the vaccine administrations 285 (Garg et al., 2020) . Another appealing procedure is the formation of chimeric VLPs.

Chimeric VLPs can be produced either by genetic fusion or by chemical conjugation. SpyCather-SpyTag methodology is an innovative decoration of VLPs via the spontaneous isopeptide bond formation (Brune and Howarth, 2018) . Recently, a vaccine of this type was synthesized, utilizing as a VLP platform the core-capsid protein 290 of AP205 phage. The platform contained antigens of P. falciparum (VAR2CSA epitope) and HPV (L2 RG1 epitope) for protection against malaria and HPV infection and its in vitro results were encouraging for the production of combinational vaccines via the use of a single VLP-scaffold (Janitzek et al., 2019) .

Lipid nanoparticles (LNPs) that are used in vaccines can be distinguished in three main categories: liposomes, virosomes and LNPs specified for nucleic acid transfer ( Figure  1B and 1C) . The word liposome comes from two Greek words: 'lipos' (λίπος) meaning 300 fat and 'soma' (σώμα) meaning body. Liposomes are lipid bilayers and can be uni-or multi-lamellar. Except phospholipids, they may also contain cholesterol, other lipids, and polymers (Demetzos, 2016) . They were discovered by Bangham in 1964 (Bangham and Horne, 1964) and in 1974 they were first mentioned as possible adjuvants in vaccine formulations by Allison and Georgiadis (Allison and Georgiadis, 1974) . 305 Nowadays, many other liposome-based formulations have been approved. Among them, there are two vaccines, Inflexal ® and Epaxal ® , both from Crucell Berna Biotech, Switzerland, for the protection against the Influenza virus and the Hepatitis A virus, respectively (Bulbake et al., 2017) . Under the right environmental pressure, phospholipids are organized into pseudo-310 spherical architectures, whose properties are highly connected with the biophysical behavior of the building blocks (Demetzos, 2016) . Hence, liposome size, lamellarity, surface charge, and bilayer fluidity vary depending on the physicochemical characteristics of the monomers and their combination (Watson et al., 2012) . The bilayer has an amphiphilic character, as the polar heads of phospholipids are oriented 315 toward the water molecules and the hydrophobic chains are placed on the internal area of the membrane (Demetzos and Pippa, 2014) . The hydrophobic interactions of the hydrocarbon chains in aqueous medium are the driving force for the liposomal structure. Due to their conformation, they can transfer both small hydrophobic molecules 320 (incorporated in the membrane) and hydrophilic ones (encapsulated in the aqueous core) (Metselaar and Storm, 2005) , as presented in Figure 1B . Furthermore, as phospholipids are the basic components of the cell membrane, liposomes have biomimicking properties and are well-tolerated non-toxic platforms (Yang et al., 2019) . They are biodegradable and usually, they do not bio-accumulate after administration. 325 Finally, they can transfer more than one antigen and, with the right surface functionalization, they can slowly release their cargo, leading to controlled-release platforms (Riaz et al., 2018) . Several studies showed that when antigenic proteins or peptides are conjugated onto the lipid membrane, the activation of defensive mechanisms is more intensive than 330 when they are encapsulated in the aqueous area (Blom et al., 2017; Serre et al., 1998) .

According to the vaccine glossary, liposomes with conjugated antigenic epitopes on their surface are called virosomes. More specifically, virosomes are produced by appropriate handling (e.g., ultracentrifuge) of the virus of interest, isolation of the membrane components and mixing with other pharmacologically inactive molecules, 335 e.g., lecithin or phospholipids (Mischler and Metcalfe, 2002) . In this way, virosomes have better biomimicking properties. Inflexal ® and Epaxal ® belong in this category. Finally, cationic lipids are preferable when the cargo is a hydrophilic, anionic molecule, i.e., siRNA and mRNA, due to the development of electrostatic interactions or hydrogen bonds between the molecules. LNPs that contain cationic lipids have the 340 ability to disrupt the endosomal and/or phagosomal membrane because of its lowdurability to proton influx (Henriksen-Lacey et al., 2011; . However, the positive charge is responsible for toxicity effects, mainly lysis of the negative charged cell membranes (Lv et al., 2006; Semple et al., 2001) . Such observations mobilized scientists to develop the category of ionizable cationic lipids (apparent pKa 345 < 6.5). Ionizable cationic lipids are charged during the manufacturing process (pH = 4) while they are uncharged in higher pH values. The main differences of these LNPs in comparison with the liposomes is that the ionizable cationic lipids are distributed mainly in the core, developing internal lipid hydrophobic areas while interacting with the nucleic acid polyanionic macromolecules. According to recent literature siRNA-350 LNPs may importantly differ in morphology, depending on the lipids molar ratio, the mixing process and the N/P ratio (ionizable cationic lipid amine to nucleotide phosphate ratio) (Akinc et al., 2019; Kulkarni et al., 2020 Kulkarni et al., , 2019 Viger-Gravel et al., 2018) . As mRNA is approximately 100-fold larger than siRNA, different morphologies might be produced when entrapping mRNA molecules ( Figure 1C ). According to the literature, 355 these platforms encapsulate mRNA into aqueous cavities inside the hydrophobic core of LNPs. PEGylated and "helper" lipids mostly cover the core, while the ionizable cationic lipids form a highly symmetrical, reverse-hexagonal, hydrophobic structure (Sebastiani et al., 2021; Yanez Arteta et al., 2018) . Interestingly Arteta et al., proved that the empty LNPs did not appear the internal reverse-hexagonal morphology that 360 was found for the mRNA loaded LNPs. Although the core is characterized as hydrophobic, aqueous cavities and channels seem to exist at approximately 24% percentage after the accomplishment of small-angle X-ray scattering (SAXS) and small-angle neutron scattering (SANS) experiments (Yanez Arteta et al., 2018) . In contrast with Arteta's group results, which demonstrate that the shell of their mRNA-365 LNPs is a lipid monolayer, other groups reported a lipidic bilayer shell of their mRNA-LNPs or other sophisticated architectures as the formation of internal liposomal-like blebs (Brader et al., 2021) . According to the above, someone can result that the exact external and the most important internal morphology of the RNA-LNPs is depended on the physicochemical characteristics of the LNP lipids as well as the manufacturing 370 processes. Figure 2 presents some of the mRNA-LNP morphologies that collected by cryo-TEM images. Although the above may conclude in higher degree of system's morphology freedom and uncertainty, they could also provide the ability to design different RNA-LNPs that provide unique entrapment and release properties. All types of LNPs proved to have enhanced immunomodulatory properties and activate 375 both CD4 + and CD8 + T-cell pathways, as well as B-cell responses (Bulbake et al., 2017) . By tailoring their morphology and physicochemical characteristics, different innate and adaptive immune responses may be possible. Larger LNPs (≥400 nm) induce T H 1 type immune response while the smaller ones (100 nm) induce T H 2 type response (Badiee et al., 2012). These may result in a significant difference in the immune 380 response as T H 1 is mostly involved with the cell-mediated immunity and phagocyte response, while T H 2 is connected with humoral immunity (Romagnani, 1999) . In conclusion, membrane fluidity affects the immunogenicity of the LNPs. More rigid liposomes, composed of saturated lipids and low concertation of cholesterol have proved more immunogenic than liposomes with lower transition temperatures and 385 higher cholesterol ratio (Kaur et al., 2014; Watson et al., 2012) .

Several polymeric NPs have been used in nanovaccinology either to entrap/conjugate 390 the antigens or to act as adjuvants ( Figure 1D ). Polymeric materials can cooperate well with many other biomaterials such as liposomes or inorganic NPs to create sophisticated nanostructures with the ability of "smart response" when administrated in vivo.

One of the most well-studied polymeric biomaterial utilized in vaccines is poly(lactide-395 co-glycolic acid) (PLGA). PLGA is a biodegradable and biocompatible material that has been approved as a vesicle from both the FDA and European Medicines Agency (EMA) for human use. Its excellent safety profile, ease of surface modification and size distribution allow the formation of unique systems with different properties (Allahyari and Mohit, 2016). PLGA formations have been studied for their ability of cargo 400 prolonged release, a beneficial property for the enhanced activation of the immune system. Dhakal et al. have extensively researched the use of PLGA for the formation of effective vaccines (Binjawadagi et al., 2014; Dhakal et al., 2017; Hiremath et al., 2016) . They have created innovative platforms against respiratory syndrome virus, H1N1 and H1N2 influenza viruses. The results after intranasal administration in pigs 405 show that both cytotoxic T-cells and T-helper cells can induce the immunity and memory mechanisms against the above pathogens. Another effort for the development of a mucosal vaccine was presented by Tallabaka et al. who developed a PLGA-based immunostimulant, covalently conjugated with a C5a receptor agonist, EP67. The modified PLGA NPs present an enhanced T-cell long-lasting mediated protection in 410 mice population (Tallapaka et al., 2019) . Finally, some studies have evaluated the value of PLGA NPs for the dual role to deliver both the antigen and the adjuvant. A PLGA nanoparticulate formulation was synthesized to encapsulate Anjelica sinensis polysaccharide as an adjuvant and ovalbumin as a model antigen. BALB/c mice, vaccinated subcutaneously with those systems, presented improved lymphocyte 415 proliferation and enhanced T H 1 and T H 2 response, resulting in promising cellular and humoral immunity . Apart from synthetic linear or grafted polymeric formulations, another group of polymeric nanoparticles has gained attention in the last years. Self-assembled protein (or peptide) NPs (SAPNs) are excellent vaccine platforms due to their biocompatibility 420 and their special morphological characteristics. SAPN architecture was inspired by the viral capsids (Doll et al., 2015) . Peptide monomers assemble into oligomers, which then form NPs, usually with an icosahedral conformation (Raman et al., 2006) , as presented in Figure 1G . The main difference with VLPs is that in the case of SAPNs, not the antigens but other peptides, which interact with the antigens, have the ability to self-425 assemble. Thus, SAPNs can be synthesized as scaffolds of antigenic epitopes that cannot self-organize in particulate systems alone. Hence, SAPN development is a rational bottom-up technique that is based on our knowledge in structural biology and biophysics to create sophisticated engineered proteins, capable to self-assemble via hydrophobic interactions (Karch and Burkhard, 2016) . 430 Many antigens have been incorporated into SAPNs, such as HIV-1 (Karch et al., 2019; Wahome et al., 2012) , Plasmodium falciparum Kaba et al., 2018 Kaba et al., , 2012 Seth et al., 2017) and bronchitis virus (J. antigenic epitopes. Some experts support that the nature of these systems give them the privilege of highly antigenic conformations that do not need an extra adjuvant. Thus, simplest systems with 435 more predictable behavior could be produced. On the other hand, the history of VLP structural formations does not confirm such hypothesis. Already licensed VLP vaccines provide higher titers of antibodies when combined with adjuvants, despite the repetitive presentation of the antigenic epitopes, as mentioned above. Based on these data, scientists have already started to study the incorporation of their SAPNs with the right 440 adjuvants to provide a safe and effective stimulation of the immune system. One of these approaches proposes that the action of the presentation of HIV-1 V1V2 loop on the surface of SAPNs can be increasingly increased by the addition of extensively studied liposomal adjuvant conformations (Karch et al., 2019) .

Gold and silica NPs are the most famous representatives of this category. Until today, no inorganic nanoparticulate-based vaccine has been approved for therapeutic or for prophylactic reasons, although experiments show beneficial results. Their "clean" and 450 stable morphology combined with their capability of high antigen payloads are some of their basic advantages ( Figure 1E ). However, their major drawback is their toxicity issues. As they are non-biodegradable materials, they may bio-accumulate in target organs and trigger unwanted immune responses and inflammatory cascade. Thus, enhanced toxicity studies remain extremely important for the understanding of their 455 absorption-distribution-metabolism-excretion (ADME) profile after in vivo administration.

Gold NP (GNP) size ranges between 2-100 nm and can be synthesized in various shapes, like spheres (Gregory et al., 2012) , rods (Tazaki et al., 2018) , cubes (Niikura et al., 2013) , nanocages, stars, prisms (Kumar et al., 2015) and nanoclusters (Wang et al., 460 2016) . All these different morphologies have been utilized for the preparation and evaluation of many prophylactic vaccines against viruses, bacteria, and parasites. The physicochemical characteristics of GNPs allow the easy conjugation with both the antigen and adjuvant by simple, even one-step procedures (Tao et al., 2017) . Quach et al. associated the immunostimulation of GNPs with their size and concentration, 465 concluding that larger chimeric particles (80 nm) showed a better efficacious and toxicological profile for vaccination against the dengue virus than the smaller ones (20 and 40 nm), after subcutaneous administration in BALB/C mice. Both CD4 + and CD8 + T-cell activation were induced, while promising nAbs titers were produced (Quach et al., 2018) . Moreover, another interesting example is the synthesis of an AuNP-M2e-470 sCPG formulation as a universal vaccine against Influenza A serotypes, as M2e is a highly conserved N-terminal extracellular portion of the M2-ion channel protein (Tao et al., 2014) . Furthermore, the addition of CpG adjuvant could additionally enhance the immunogenicity of the vaccine. Indeed, this formulation has proved to be effective after intranasal administration to mice, by inducing high titers of IgG antibodies and memory 475 B-cells, even in elderly mice (Bimler et al., 2019) .

Silica nanoparticles (SiNPs) can form either core-like, non-porous spherical structures (Thalhauser et al., 2020) or mesoporous morphologies (Ferreira Soares et al., 2020) . Concerning solid SiNPs, the antigenic protein can be either adsorbed on the surface of the particle or conjugated by covalent bonds, while in the mesoporous SiNPs, the 480 antigen is encapsulated into the porous and can be stabilized by electrostatic or hydrophobic forces . Additionally, positive charge appears to further improve the cellular uptake of the SiNPs from APCs (Amin and Boateng, 2020). As unfunctionalized SiNPs are negatively charged, due to the silanol groups on their surface , additional positively charged moieties could be added 485 (Amin and Boateng, 2020). A promising study from Bai et al. showed that hollow mesoporous silica nanoparticles loaded with VLPs for the prophylaxis against the footand-mouth disease virus (FMDV) presented better immunostimulating results in comparison with the use of VLPs immunomodified with Freund's complete adjuvant after IM administration to guinea pigs. High antibody titers as well as INF-γ and 490 proliferation of T-cells were induced (Bai et al., 2019). Moreover, Huang et al. assume that mesoporous SiNPs of 200-400 nm have the best size and pore diameter for the activation of the innate cellular immune response . Mahony et al. reported that amino-functionalized mesoporous SiNPs of 90 nm diameter presented better humoral and cellular immune response against ovalbumin in comparison with a 495 higher quantity of ovalbumin subunits adjuvanted with QuilA, a famous immunomodulator saponin mixture, after IM administration to mice. The pre-clinical trial showed that the functionalized mesoporous SiNP formulation, additionally to its promising adjuvant and delivery platform properties, it did not present any morphological changes of high-risk organs and tissues (kidneys and spleen) (Mahony 500 et al., 2013) .

Although viral vectors do not belong in nanoformulations, they are biological platforms 505 in the nanoscale ( Figure 1F ). The first effort to create such a vaccine started from Moss and colleagues in 1984 for the protection from HBV infection, using the vaccinia virus (Moss et al., 1984) . Today, after the authorization of three five viral vector-based vaccines and the subscription of many such formulations in clinical trials, their use remains a taboo. Causes for the aloofness are safety issues, as recombinant viruses, 510 attenuated or not, promote the immunity against another pathogen via the infection of the host cells. Many modern technologies and different viral species were tested to verify the safety and efficacy of these formulations. Genetic engineering processes modify live viral vectors, either replicating (usually attenuated) or non-replicating, to encode heterogenous antigens. This technique is 515 mainly achieved by the insertion of the desirable antigen genes and the deletion of the possibly harmful ones. Certain pathogen-associated molecular patterns (PAMPs), present in the surface of the viral platforms, result in a more effective recognition from the cells of the immune response than the use of a subunit antigen. Thus, the addition of an adjuvant is usually unnecessary, decreasing the complexity and the cost of the 520 vaccine (Ewer et al., 2016) . In many cases, the antigen delivered by those platforms is not expressed in the virus, but it is expressed after the infection of the host cell by the translational and post-translational mechanism of the second one, via the virus replication cycle. The major advantage of the above is the correct protein conformation and glycosylation that reassures an effective presentation motif and a potent immune 525 response (Rauch et al., 2018) . After the absorption of the virus from the host cell and the expression of the immunogenic protein, the protein can be presented by the MHC I and activate the CD8 + T-cell pathway (Ewer et al., 2016) . Despite all these unique properties of the viral vectors, some serious concerns remain about their mechanism of action and subsequently, their safety. Synthesis of antibodies 530 against the vector is the main drawback of these platforms. As a result, in the case of human viruses, a high human seroprevalence for certain strains results in quick recognition and inactivation of the virus before the promotion of the immunity against the desirable antigen. This problem is clear in the case of human adenoviruses (Ads) (Coughlan, 2020) . They are classified in two main categories, human Ads (HAds) and 535 non-human primate Ads. Ad5 is a HAd that has been extensively studied as a viral vector with encouraging results for the prevention of many pathogens due to the ease of its genetic modification (Humphreys and Sebastian, 2018; Rauch et al., 2018) . Ad5 is a common virus and large human populations, already appearing to be Ad5seropositive, decreasing the efficacy and the predictability of this platform (Buchbinder 540 et al., 2008) . Hence, rarer human Ads, such as Ad35 (Crank et al., 2016) and chimpanzee Ad (ChAd) are preferable (Osman et al., 2017; Tiono et al., 2018) . In some cases, different viral vectors are utilized for the first and the booster dose, to reassure the activation of the immune response (Crank et al., 2016) . The history of viral evolution has shown that their behavior is sometimes unpredictable. 545 Certain EU regulations are active at the moment for the evaluation of viral vehicles to reassure the safety of both the vaccines and the environment (Baldo et al., 2013). The recent example of an authorized by the FDA and EMA vaccine against dengue, utilizing the yellow fever virus as a vector (EMA, 2020c), reminds us that these innovative vaccine platforms have not been studied for a long period and thus, extensive trials are 550 necessary. In 2015, Dengvaxia® was licensed in the Philippines for protection of 9-45 years old people against dengue. Two years later, the vaccination program was terminated due to suspicions that Dengvaxia® caused increased danger for aggressive infection from the dengue virus (Halstead, 2018) . Indeed, post-hoc clinical trials and samples re-analysis from Sanofi verified the concerns. Dengvaxia® proved to increase 555 the risk of severe dengue and dengue hospitalization in seronegative populations, mostly for children, and was related to some deaths (Sridhar et al., 2018) . This effect on seronegative population is a result of the dengue virus nature and is not correlated with the viral vector. After these events, Dengvaxia® was licensed from the FDA and EMA in 2018 only for people 9-45 years of age who live in areas where the disease is 560 epidemic and have already been infected once from the virus in the past (EMA, 2018) .

Unlike Dengvaxia®, Imojev® (Sanofi Pasteur), the first viral vector vaccine seems to has great efficacy and safety results. It is a modified yellow fever virus (YFV17D) that encodes two envelope proteins of the Japanese encephalitis SA 14-14-2 strain. Imojev® is currently licensed in a plethora of countries with high epidemic risks (Kim et al., 565 2020; Ma et al., 2020; WHO, 2013) . Interestingly, the live attenuated JE SA 14-14-2 vaccine is now evaluated for the ability of cross-protection against other similar mosquito-borne flaviviruses (R. . Such a result could be extremely positive, as many of the flaviviruses co-exist in epidemic dangerous areas. Finally, the three authorized vaccines for protection against Embola virus belong in this 570 vaccine category, as well. Ervebo TM (rVSVΔG-ZEBOV-GP), the first authorized Embola vaccine, and the only one fully approved from both EMA and FDA (2019) 

The word "adjuvant" comes from the Latin "adjuvare", which means "to help". According to the EMA: "A vaccine adjuvant is a component that potentiates the immune responses to an antigen and/or modulates it towards the desired immune responses" (EMA, 2005) . Depending on the type of the pathogen, different categories 595 of adjuvants can be used to provide the best result (Petrovsky and Aguilar, 2004) .

Adjuvants alone do not have an immunogenic ability, but when co-administrated with an antigen, they activate the innate mechanisms of the immune system and improve the efficacy of the vaccine. The activation is triggered by the recognition of adjuvant domains from the cellular PRRs. According to the active EMA guidelines, even if an 600 adjuvant does not present serious adverse effects, its use must also be beneficial and improve the safety and efficacy profile to be approved (EMA, 2005) . Below, we review some of the most common and promising innovative adjuvants of nanoscale.

Immune-stimulating complexes (ISCOMs) were first described by Morein and colleagues in 1984 and since then, an evolution in the adjuvant technology arrived (Morein et al., 1984) . They are spherical cage-like structures of an approximately 40 nm diameter and they consist of cholesterol, phospholipids, specific saponins from 610 Quijalla saponaria and incorporated antigens (Reimer et al., 2012) . Later, it was noted that the incorporation of the ISCOM formulation with the antigen is not necessary for the immunomodulatory character of the adjuvant and empty ISCOM particles were developed. These particles are now called ISCOM-matrix ( Figure 1G ) and their main representative is Matrix-M™. Matrix-M™ consists of two different types of NPs, 615 Matrix-A and Matrix-C (7:3). These NPs differ in the saponin fraction (Fraction-A and Fraction-C respectively) (Hu et al., 2005; Magnusson et al., 2018; Skene et al., 2008) . A negative surface charge is present due to the glucuronic acid of the S. saponaria saponins. This charge is useful for electrostatic interactions with positively charged antigens and also provides physicochemical stability in the system's conformation 620 (Pearse and Drane, 2005) .

As early as 1997, it was proposed that ISCOMs induce both T H 1 and T H 2-mediated immune responses (Magnusson et al., 2018) , while in 2012, a study took place for the evaluation of the mechanism of action of Matrix-M™ in murine. The results showed an increase of leucocytes and DCs in lymph nodes in a murine model (Reimer et al., 625 2012) . The ISCOMATRIX formulation promotes high levels of both humoral (high titers of specialized antibodies) and cellular (Ag-specific CD8 + T-cells) immunity, while a plethora of chemokines and cytokines contribute to generate a potent, robust and long-lasting immune response (Morelli and Maraskovsky, 2017) .

Although conventional o/w emulsions have been effectively used in many prophylactic vaccines, nanoemulsions ( Figure 1H) show a more efficient and safer profile. According to the literature, higher immunogenicity and milder topic reactions are 635 observed after the use of o/w nano-emulsions in comparison with larger-sized emulsion droplets (Shah et al., 2014) . In this review, we analyze the MF59 and AS03 o/w nanoemulsions. The MF59 adjuvant has been utilized in seasonal and pandemic influenza vaccines. The first MF59 adjuvanted vaccine was licensed from FDA in 1997 by the trade name 640 Fluad ® (Seqirus Inc.) as an inactivated influenza vaccine for elderly populations. Till today, four more MF59 adjuvanted vaccines are authorized (Focetria ® , Celtura ® , Aflunov ® and Fluad Tetra ® ). MF59 contains squalene (4.3% w/w) and the surfactants Tween 80 (0.5% w/w) and Span 85 (0.5% w/w). The size of the droplets is approximately 160 nm (O'Hagan, 2007) . The nanoemulsion is biocompatible, bio-645 degradable, and non-toxic (Kommareddy et al., 2017) . As to the MF59 mechanism of action, it mainly promotes a T H 2 response. Morel et al., 2011) . AS03 has been utilized in vaccines against avian influenza (H5N1) and the H1N1 influenza pandemic (2009). During the pandemic, two AS03-containing vaccines were authorized, one in Europe (Pandermix) and one in Canada (Arepanrix). One year after, Pandermix was associated with narcolepsy syndrome in the adolescent population and until 2015, more than 1300 cases 660 had been reported in the EMA EudraVigilance database. Although the mechanism of this adverse action might correlate with the production of an antibody for an influenza nucleoprotein and not with the existence of AS03, more research is necessary on the subject (Ahmed et al., 2018; Johansen et al., 2018) . It is also of exceptional importance to research whether the same result would appear after immunization of a non-665 adjuvanted vaccine or with the use of another similar adjuvant, as AS03 may not be the major causative of narcolepsy but the driving force.

670 After the evaluation of the saponin QS-21 and the 3-O-desacyl-4'-monophosphoryl lipid A (MPL) immunostimulating possibilities and dangers, the GlaxoSmithKline (GSK) and US Army developed liposomal platforms -AS01 (AS01 B and AS01 E ) -to incorporate the above constituents (Figure 3) . Two vaccines containing AS01 B have been approved, Shingrix and Mosquirix. According to the EMA risk-management plan, 675 updated in 2019, one of the adverse effects that have been observed and associated with the administration of Mosquirix is febrile convulsion in subjects 5-17 months and it shall further be investigated (EMA, 2019b (EMA, , 2015 . The liposomal formulation of these materials decreases the hemolytic danger caused by QS-21 as high doses of QS-21 can cause lysis of the plasma membranes of erythrocytes, 680 due to the amphiphilic behavior of the molecule (Lacaille-Dubois, 2019). This action is correlated with the interaction of QS-21 with the plasma cholesterol, leading to the formation of pores and defects of the membrane bilayer. Furthermore, the chemical instability of QS-21 should also be taken into consideration as the pure mixture of the saponins is thermo-and pH-sensitive, leading to hydrolytic diacylation (Ragupathi et 685 al., 2011) . Hence, the production of an adjuvant system with a liposomal structure that contains cholesterol, orientates QS-21 to interact with the cholesterol of the liposomes rather than the cell membrane cholesterol. AS01, as well as a similar system developed by the US Army, called Army Liposome Formulation containing QS-21 and MPL (ALFQ), can develop sophisticated architectures that protect from hemodialysis and 690 orientate the eight sugars of QS-21 in a conformation visible for interaction with the lectin receptors, present on the surface of the cells of innate immune system (Alving et al., 2020)

695 After one and a half year since the first cases of COVID-19, more than 216 million cases have been identified and more than 4,5 million people have lost their life due to SARS-CoV-2. According to numbers, the above approaches the population of the New Zeeland. Recently, four COVID-19 vaccines have been authorized by the FDA and the EMA (emergency use authorization in U.S. and conditional market authorization in 700 EU) and more are used in other territory regions, such as in China and Russia. 

715 Three non-replicating viral vector (VVnr) vaccines have been approved by the UK Medicines and Healthcare Regulatory Agency, EMA, FDA, and the regulatory authorities of Russia by the names AZD1222 (authorized by EMA), Sputnik V (under rolling review in EU and US), and Janssen COVID-19 vaccine. The first one, which was developed by the University of Oxford and AstraZeneca, utilizes the replication-720 deficient chimpanzee Adenovirus ChAdOx1 to carry the structural surface glycoprotein antigen (S-protein) gene (Voysey et al., 2021) . The second one was developed at the Gamaleya Research Institute of Russia and consists of two different human recombinant Adenoviruses -rAd5 and rAd26. Both vectors carrying the full-length Sglycoprotein gene of SARS-CoV-2. Although it is not always clarified in the literature, 725 the term combined vaccine means that the subjects' first dose of the vaccine is with the one vector and the second dose contains the other vector. Hence, we are talking about two different formulations that are used each time (Logunov et al., 2020) . Why such an administration design is necessary has the same answer as the question of why different dosage schedule gave better results for ChAdOx1 nCov-19 vaccine: seropositivity to 730 the vector, as mentioned above. To minimize this phenomenon, Sputnik V takes advantage of the two types of Ads, while ChAdOx1 nCov-19 highlights that when the first booster dose is lower than the second one, higher efficiency is achieved. Specifically, administration of low dose/standard dose provided 90% efficiency while administration of stand dose/ standard dose provided approximately 65% efficiency in 735 group populations 18-55 years old. Interestingly, a phase 1/2 clinical trial (NCT04684446), sponsored by AstraZeneca, evaluates whether AZD1222 vaccine can be given in combination with the rAd26 strain of Sputnik V vaccine, as well as the dose timing of these two vaccine doses. In contrast with the above two vaccines, the COVID-19 vaccine that was developed by 740 Janssen Pharmaceutical (Johnson & Johnson) , is authorized as an one-dose vaccine. In fact, it is the only one-shot authorized COVID-19 vaccine. According to the clinical trials result, the vaccine showed 66.3% efficiency two weeks after the vaccination while further effectiveness could be succeeded after a second dose. Janssen's vaccine utilizes human Ad26 virus as a vector to transfer the immunogenic information to activate the 745 immunity. The CanSino Biological vaccine, based on the rAd5 virus, also provides protection against SARS-CoV-2 after a single immunization and is currently under phase 3 evaluation . All these four vaccines are administrated intramuscularly (IM). Two pharmaceutical companies, Vaxart and ImmunoBio, have developed oral vaccines against SARS-CoV-750 2, currently in phase 1 and 1/2 trials, respectively. Both vaccines utilize Ad5 as a vector but the Vaxart formulation is enriched with a TLR agonist (dsRNA) (Jin et al., 2010; Poteet et al., 2016) . According to WHO, 4 vaccines based on replicating viral vectors are in clinical evaluation worldwide. The mechanism of action for these vectors is the same with 755 Imojev ® and Dengvaxia ® formulations, meaning that the chimeric vectors have the potential to replicate but they can barely cause illness due to the vector. Although viral vector vaccines have proved to be highly effective and safe, concerns about some very rare side effects have arisen, specifically unusual blood clots with low blood platelets. According to EMA data, AZD1222 (Vaxzevria) can cause such clots in 760 1/100,000 of vaccinated people (EMA, 2021) . The FDA has reported some similar cases after immunization with Janssen's vaccine (Shay et al., 2021) . These clots seem to be correlated with the production of platelet factor 4 (PF4) antibodies and the pathogenicity is known as the VIPIT (vaccine induced prothrombotic immune thrombocytopenia) syndrome (Greinacher et al., 2021; Scully et al., 2021; Thaler et al., 765 2021) . Although very rare, VIPIT is a serious adverse effect, capable to cause high level of vaccine hesitancy. Thus, some European countries chose to use Vaxzevria only in older populations, where the danger of severe disease and death after infection from SARS-CoV-2 is higher, while other vaccines are preferred for younger people.

As mentioned above, RNA vaccines are promising vaccines because they combine high effectiveness and safety with cost-effective and rapid manufacturing processes. Moreover, the RNA modification to cover protection against SARS-CoV-2 variants is 775 easily feasible. Evidence of that is the authorization of the two first COVID-19 vaccines by EMA and FDA. Pfizer/ BioNTech's and Moderna's technology is based on the encapsulation of mRNA molecules into LNPs (Table 3) . Both are administrated IM and two doses are necessary to provide a high level of protection against SARS-CoV-2. The first one is currently the only COVID-19 vaccine that has received a standard 780 marketing authorization while the rest vaccines have received a conditional marketing authorization. Pfizer/BioNTech's vaccine (BNT162b2 -30 mg per dose) encodes a membraneanchored SARS-CoV-2 full-length spike, stabilized in the prefusion conformation (Walsh et al., 2020) . As it is mentioned in the Summary of Product Characteristics 785 (SPC) of the vaccine, the other excipients included are an ionizable cationic lipid (ALC-0315), a surfactant PEGylated molecule (ALC-0159), cholesterol and a helper phospholipid (Distearoylphosphatidylcholine DSPC). The mentioned biomaterials form the LNPs that encapsulate the mRNA molecules into internal aqueous cavities. The result of a phase 2/3 trial showed 95.0% vaccine efficacy and limited, mostly mild 790 adverse events. Some of the serious but rare adverse events are shoulder pain, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia, and right leg paresthesia. HIV, HBV and HCV positive patients, as well as older populations or populations with other chronic diseases were included in the trials, but people with other immunodeficiencies were excluded. Evaluation processes will continue for two 795 years after the second administration, so that more reliable results will be obtained (Polack et al., 2020) . Although this vaccine seems to have a beneficial profile, it must be stored at -80°C (Mishra and Tripathi, 2021) . These storage conditions hinder vaccination in low-income countries.

Moderna's vaccine, on the other hand, is stable inside a typical refrigerator (2-8°C) for 800 one month and for seven months at -25°C to -15°C. The mRNA (mRNA-1273) encodes the stabilized prefusion SARS-CoV-2 spike protein. Some of the mRNA modifications are similar to ones in Pfizer's mRNA (5'cap, 3'UTR and poly(A) tail) and target in higher stability of the molecule (Corbett et al., 2020) . Although the manufacturing processes are not fully transparent at the moment, due to active patents, we hypothesize 805 that except for mRNA stability differences, the differentiation in the storage temperature between the two vaccines is mainly owed to the materials of the LNPs. Moderna's LNP formula contains SM-102 as an ionizable cationic lipid, DSPC, cholesterol and polyethyleneglycol 2000 -dimyristoyl glycerol (PEG2000 DMG). Both platforms use the same system for the development of the LNPs (ionizable 810 lipid:DSPC:cholesterol:PEGylated surfactant). However, the morphology of the two ionizable lipids, ALC-0315 and SM-102, is importantly different (e.g., in the number of hydrophobic tails). Moreover, the molar ratios between the utilized biomaterials are currently unknown. All of the above result in two LNP platforms with a unique physicochemical profile. 815 Finally, the CVnCoV vaccine was designed by CureVac AG and is currently under rolling review from EMA. CVnCoV is a lipid nanoparticulated platform that encapsulates an unmodified mRNA and leads to a more physical activation of the immune system. According to CureVac declarations, the vaccine is stable and effective for at least three months in a regular refrigerator (5°C). While this vaccine is almost on 820 the market, GSK and CureVac AG agreed to develop a next-generation vaccine that will be effective in multiple variants and mutations of SARS-CoV-2, confirming the adaptability of this vaccine technology against the variants. Four other LNP-mRNA platforms are in early-stage evaluation.

Novavax is the only pharmaceutical industry, at the moment, that developed not only an antigenic nanosystem but also a nano-adjuvant vaccine (NVX-CoV2373 -0.5 mL). NVX-CoV2373 contains a recombinant nanoparticulate platform (rSARS-CoV-2, 830~27.2 nm and a nano-adjuvant and is almost ready to be authorized by the medicine agencies. The platform is formed by the self-assembly of the trimeric, full-length, wild type S-glycoprotein SARS-CoV-2. The protein monomers are expressed, assemble into nano-micelles and are purified by baculovirus Spodoptera fruigiperda (Sf9) insect cells (Tian et al., 2020) . The vaccine is adjuvanted with Matrix-M1 that has been extensively 835 described above. The vaccination process requires 2 IM injections, 21 days apart.

rSARS-CoV-2 and Matrix-M1 are separately stored at 2-8°C and mixed right before the administration (Keech et al., 2020) . Hopefully, NVX-CoV2373 seems to be efficacious against both the UK and South Africa variants, according to Novavax. However, scientific reports and results are necessary to confirm this claim. 840

The programming of each immune cell that receives certain information from its environment, as well as the interaction with other cells of the immune system is the 845 reason for the production of an effective response. The ability of the immune system to receive and respond immediately to a plethora of different messages is remarkable, noting that immune cells are "blind" to recognize information that does not activate its receptors. We should not correlate its function with a binary self-not-self algorithm. Interestingly, researchers correlate our immunity mechanism of action with artificial 850 intelligence terms, such as crowd wisdom and machine learning (Cohen and Efroni, 2019) . We would like to bring these observations a step further and connect them with quantum mechanics. Principles such as the impossibility to differentiate the input and output, the hardware (chemistry) from the software (bio-information) and the immediate communication and interaction of a population (crowd wisdom) are basic 855 phenomena observed in the science of quantum computation (Davies, 2004) . Indeed, several important decisions of the immune system are based on events that happen in the nanoscale, where quantum effects are proven to exist (McFadden and Al-Khalili, 2018) . In regard to the above, it is beneficial to repurpose formulations in the nanoscale as 860 vaccine platforms. The results of their use in vaccine technology can be placed into three basic axes: a) low cost, b) efficiency, and c) safety. Firstly, nanotechnology can be useful for the development of innovative platforms that can be administrated via alternative routes, including intranasal, (Marasini et al., 2017; Nakahashi-Ouchida et al., 2018) intradermal (Al-Zahrani et al., 2012; Caucheteux et al., 2016) or mucosal 865 (Faruck et al., 2020; Johnson et al., 2020; Zhang et al., 2018) administrations. Although these sophisticated formulations might seem expensive, the final immunization per person cost can be decreased due to the minimization of doses, the ability to combine more than one antigenic epitope, the development of multifunctional chimeric vaccines (cross-protection) and the lower storage cost. 870 Secondly, due to the high surface-to-volume ratio of nanoscale systems, enhanced immunogenicity of both innate and adaptive immunity can be induced. Furthermore, the enrichment of such formulations with the right adjuvant that will activate certain pathways of the immune response can target specific key cells. HIV-1 (Brinkkemper and Sliepen, 2019) , Zika (Shanmugam et al., 2019) and Ebola (Yang et al., 2017) are 875 some of the viruses on which nanovaccines have shown promising results. Not surprisingly, many of the currently authorized vaccines against SARS-CoV-2 are based in nanotechnology. These innovative vaccines provide extremely high level of efficiency, more than 65% and in some cases more than 90%, including difficult subpopulations, such as older people with comorbidities. 880 In vivo trials, as well as human trials are necessary today for the development of immunogenic and safe vaccines. Because of ethical issues, scientists are trying to find effective methods to decrease the number of subjects that are necessary in vaccine and drug development. We hypothesize that systems biology and 3D bioprinting will have a promising contribution to accomplishing the above purpose. Over the last years, it has 885 been evident that a disease is not attributed to a single factor but instead, several complex processes are taking place at the same time. Systems biology uses big datasets of the 'omics' -transcriptomics, metabolomics and proteomics -and predicts the behavior of a biologic system, for instance, a cell, tissue, organ, or even a living organism to certain stimuli (Schneider and Klabunde, 2013) . Developing in silico 890 models that could forecast the systemic effect of the administration of an active substance could minimize the number of in vivo trials. Assessment of critical process parameters and optimization of quality by design (QbD) processes could be the first fields of pharmaceutical manufacture that will take advantage of systems biology (Richelle et al., 2020) . 895 3D bioprinting is another innovative idea for minimizing in vivo preclinical and clinical trials. 3D bioprinting utilizes smart thermo-responsive biomaterials, mainly polymers, that are biodegradable, to synthesize highly hierarchical structures of medicinal implants, tissues, or organs (Lee and Cho, 2016) . Except for the designing of complex scaffolds or extracellular matrixes (ECM), modern bioprinters can also deposit cells. 900 Organs-on-a-chip is a promising idea based on the microfluidic technology.

Microfluidic organ-based platforms could be manufactured by high-technology bioprinters with the prospect of mimicking the functionality of real organs. Thus, scientists can study the effects of administrating a certain formulation (e.g., a vaccine) in a human-like chip of only some micrometers diameter (Sun et al., 2020) . Recently, 905 chips that connect more than ten compartments/organs have been produced, as presented in Figure 4 , and their ability to correctly predict the real pharmacokinetic and/or pharmacodynamic in vivo behavior in different stimuli is in evaluation stage (Berthier et al., 2020; Novak et al., 2020) . According to all the above, we propose that universal medicine agencies, such as the 910 EMA and the FDA, should recognize the benefits of utilizing innovative technologies that are taking place in the nanoscale for the development of high quality, efficient, safe, and economically affordable vaccines and adopt the right legislative framework. In this way, not only high, but also low-income countries can have access to effective and safe vaccines the most important human privilege: human health. Standard, well-915 characterized, safe vaccine platforms are the key parameters to develop quickly vaccines against epidemic viruses.

The present review outlines the innovative vaccine platforms and their role in the design 920 and production of safe and effective COVID-19 vaccines. These platforms can transfer both antigens and adjuvants. Each class of these platforms provides certain advantages and disadvantages, the knowledge of whom will lead to the most effective selection for each pathogen. Three main vector types can be classified by the type of active substance they deliver -protein 925 subunits, nucleic acids, or immunostimulant molecules. Each platform is responsible for a unique activation of the human immune system, due to a different antigen presentation. The presentation is highly connected with the platform's structure and stability. Thus, the physicochemical and morphological characteristics of each vaccine platform affect the final functionality of the system and finally the vaccine 930 effectiveness.

The incorporation of biomaterials that belong in different categories, such as lipids and polymers could result in the development of "smart" delivery nanoplatforms i.e., LNPs that interact with their environment and release the desired antigenic information to the target immune cells. 935 On the other hand, viral vector vaccines have the ability to incorporate the antigenic information into their genetic code and via a non-pathogenic infection of the host cells, mimic the natural infection route of the virus. Subunit formulations self-assemble into nanosystems with a highly organized and responsive morphology. The surface of these systems presents certain areas of the 940 antigenic proteins, the epitopes, in a way that the activation of the immune process is more intense and effective. Finally, even when the immunogenicity of the formulation is low, the addition of an adjuvant system with immunostimulant factors can lead to an effective immune response. Although a nanosystem that contains the adjuvant is not always necessary, in 945 some cases the platform can significantly reduce the toxicity of the adjuvant and/or increase the immunostimulant properties. The COVID-19 pandemic has up till now resulted in the loss of a population that overcomes the population of a small country i.e., Croatia. Such an aggressive virus and a threatening health issue resulted in a worldwide coordinated effort to fight against the 950 virus spread and boosted the development of innovative vaccine platforms. Although these nanoscale vaccines thrived under an emergency situation, their results are highly promising for the design of future vaccines against other pandemics or even existing viruses for whom effective vaccines have not been found yet. 1770 Figure 4 : Multi-organs-on-chip illustration. Organs-on-chip are microfluidic devices that could significantly decrease the number of human subjects needed for the evaluation of novel vaccines in pre-clinical and clinical phases.

Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-1030 Bound or Soluble Antigen

Encapsulation state of messenger RNA inside lipid nanoparticles

Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies

New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue . Front

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Liposomal formulations in clinical use: An updated review

Malaria vaccine based on self-assembling protein 1050 nanoparticles

Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1

Natural killer cell memory in infection, inflammation and cancer

Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices

Adjuvant formulations for virus-like particle (VLP) based vaccines

The immune system computes the state of the body: 1070 Crowd wisdom, machine learning, and immune cell reference repertoires help manage inflammation

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Factors Which Contribute to the Immunogenicity of Nonreplicating Adenoviral Vectored Vaccines

BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

Follicular Helper CD4 T Cells (TFH)

Quantum Mechanics and the Origin of Life

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

Harnessing dendritic cells for immunotherapy

Advanced drug delivery nanosystems (aDDnSs): a mini-review

Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs

Optimizing the design of protein nanoparticles as carriers for vaccine applications

AstraZeneca's COVID-19 vaccine: benefits and risks in context. Paracoccidioides brasiliensis

US Package Insert

Imojev: US Package Insert

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus

Hepatitis B small surface antigen particles are octahedral

Harnessing nanoparticles for immunomodulation and vaccines

Conjugation of Y. pestis F1-antigen to gold 1200 nanoparticles improves immunogenicity

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Angelica sinensis polysaccharide encapsulated into PLGA nanoparticles as a vaccine delivery and adjuvant system for ovalbumin to promote immune responses

Which Dengue Vaccine Approach Is the Most Promising, and 1210 Should We Be Concerned about Enhanced Disease after Vaccination?: There Is Only One True Winner

Natural killer cell specificity for viral infections

Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-dimethylaminoethane)carbomyl] cholesterol

Toward a universal flu vaccine

Entrapment of H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T Cell Response and Vaccine Efficacy in Pigs

B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen

The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREPTM703

Macrophage-like THP-1 cells show 1240 effective uptake of silica nanoparticles carrying inactivated diphtheria toxoid for vaccination

Novel viral vectors in infectious diseases

Understanding Subset Diversity in T Cell Memory

A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine

NOD2 and TLR2 ligands trigger the activation of basophils and eosinophils by interacting with dermal fibroblasts in atopic dermatitis-like skin inflammation

Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant

74 -Immunization in Europe

Nanoparticle Technology 1265 for Respiratory Tract Mucosal Vaccine Delivery

Selfassembling protein nanoparticles with built-in flagellin domains increases 1270 protective efficacy of a Plasmodium falciparum based vaccine

Protective Antibody and CD8+ T-Cell Responses to the Plasmodium falciparum 1275

Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric 1280 conformation as vaccine antigen

Vaccine technologies: From whole organisms to rationally designed protein assemblies

The role of regulatory T cells in immunopathogenesis and immunotherapy of viral infections

Effect of Incorporating Cholesterol into DDA:TDB Liposomal Adjuvants on 1290 Bilayer Properties, Biodistribution, and Immune Responses

Recombinant Spike Protein Nanoparticle Vaccine

1300 Vaccine-derived polioviruses and the endgame strategy for global polio eradication

Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live

Japanese Encephalitis Chimeric Virus Vaccine (Imojev®) in South Korea

Chapter 13 -MF59: A Safe and Potent Adjuvant for Human Use

Differentiation of germinal center B cells into plasma cells is initiated by highaffinity antigen and completed by Tfh cells

Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles

On the role of helper lipids in lipid nanoparticle formulations of siRNA

Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached 1325 gold nanoparticles

Memory B cells

Updated insights into the mechanism of action and 1330 clinical profile of the immunoadjuvant QS-21: A review

One-step fabrication of an organ-on-a-chip with spatial heterogeneity using a 3D bioprinting technology

Development of mRNA vaccines and their prophylactic and therapeutic applications

The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in 1340 autoimmune disease

A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus

The development of a recombinant hepatitis E vaccine HEV 239

Lysine-1350 containing cationic liposomes activate the NLRP3 inflammasome: Effect of a spacer between the head group and the hydrophobic moieties of the lipids

The C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host Interaction

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, nonrandomised phase 1/2 studies from Russia

Virus-like particle vaccine with B-cell epitope from porcine epidemic diarrhea virus ( PEDV ) incorporated into hepatitis B virus core capsid provides clinical alleviation against PEDV in neonatal piglets through lactogenic immunity

Toxicity of cationic lipids and cationic polymers in gene delivery

Adverse events following 1380 immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan

Matrix-M TM adjuvant enhances 1385 immunogenicity of both protein-and modified vaccinia virus Ankara-based influenza vaccines in mice

Mesoporous Silica Nanoparticles Act as a Self-Adjuvant for Ovalbumin Model 1390 Antigen in Mice

Nanoparticles target distinct dendritic cell populations according to their size

Intranasal delivery of nanoparticle-1395 based vaccines

The origins of quantum biology

Dendritic Cells: Master Regulators of the Immune Response

Liposomes in the treatment of inflammatory disorders

Live attenuated vaccines: Historical successes and current challenges

Inflexal®V a trivalent virosome subunit influenza vaccine: Production

One year update on the COVID-19 pandemic: Where 1410 are we now?

Major findings and recent advances in virus-like particle (VLP)-based vaccines

Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped 1420 viruses

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

Chapter 16 -ISCOMATRIX Adjuvant in the Development of Prophylactic and Therapeutic Vaccines

Live recombinant vaccinia virus protects chimpanzees against hepatitis B

Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases

Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host&#x2019;s Response to Pathogens

Gold nanoparticles as a vaccine platform: Influence of size and shape on immunological responses in vitro and in vivo

Virus-like particles as immunogens

Sontheimer-1455

Robotic fluidic coupling and interrogation of multiple vascularized organ chips

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection

The mechanism of action of MF59 -An innately attractive adjuvant formulation. Vaccine

A Vaccine against Ebola Virus

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

ISCOMATRIX® adjuvant for antigen delivery

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV

Recent Progress on the Versatility of Virus-Like Particles

Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

Structure-based 1500 design of peptides that self-assemble into regular polyhedral nanoparticles

New vaccine technologies to combat outbreak situations

Matrix-M TM Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen

Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review

Towards a widespread adoption of metabolic modeling tools in biopharmaceutical industry: a process systems biology engineering perspective

Th1/Th2 cells

Understanding drugs and diseases by systems biology?

Material design for lymph node drug 1525 delivery

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of 1535 mRNA-Containing Lipid Nanoparticles

Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable 1540 aminolipids: formation of novel small multilamellar vesicle structures

Efficient Presentation of Multivalent Antigens Targeted to Various Cell Surface 1545 Molecules of Dendritic Cells and Surface Ig of Antigen-Specific B Cells

Development of a selfassembling protein nanoparticle vaccine targeting Plasmodium falciparum 1550

Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants

The impact of size on particulate vaccine adjuvants

Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine -United States

Enhanced immune response to 1565 hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine

Evaluation of ISCOMATRIX TM and ISCOM TM vaccines for immunisation against Helicobacter pylori

Applications of nanotechnology for immunology

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

The History Of Vaccines And Immunization: Familiar Patterns

Combining additive manufacturing with microfluidics: an emerging method for developing novel 1585 organs-on-chips

Chapter Eleven -Virus-Like Particles

Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after 1595 respiratory immunization and subsequent T-cell-mediated protection against respirat

Consensus 1600 M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses

Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus

Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines

Plasmid-DNA lipid and polymeric nanovaccines: a new strategic in vaccines development

Successful treatment of vaccineinduced prothrombotic immune thrombocytopenia (VIPIT)

Envelope Trimers on the Surface of Silica Nanoparticles

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

First field efficacy trial of the ChAd63 MVA ME-1635 TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Ebola virus disease: current vaccine solutions

Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan

Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic 1645 Nuclear Polarization-Enhanced NMR Spectroscopy

Commonly Used Adjuvant Human Vaccines: Advantages and Side Effects

The role of basophils in helminth infection

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Conformation-specific Display of 4E10 and 2F5 Epitopes on Selfassembling Protein Nanoparticles as a Potential HIV Vaccine

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Assembly of hepatitis E vaccine by 'in situ' growth of gold clusters as nano-adjuvants: an efficient way to enhance the immune responses of vaccination

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine

Recombinant Erns-E2 protein vaccine formulated with MF59 and CPG-ODN promotes T cell immunity against bovine viral diarrhea virus infection

Design considerations for liposomal 1695 vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens

Development of Pandemic Vaccines

Japanese Encephalitis Vaccines: WHO position paper -February 2015 = Note de synthèse : position de l'OMS à propos des vaccins contre l'encéphalite japonaise -février 2015

Annex 1: Recommendations for the production and quality control of smallpox vaccine, revised

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Viruses 12

Successful reprogramming of cellular protein production through mRNA 1715 delivered by functionalized lipid nanoparticles

Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases

Ebola Vaccination Using a DNA Vaccine Coated on PLGA-PLL/γPGA Nanoparticles Administered Using a Microneedle Patch

Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine

Induction of crossneutralizing antibodies by sequential immunization with heterologous 1730 papillomavirus L1VLPs and its implications for HPV prophylactic vaccines

Rationally Designed Self-Assembling Nanoparticles to Overcome Mucus and Epithelium Transport Barriers for Oral Vaccines against 1735 Helicobacter pylori

Virus-like particle-based human vaccines: Quality assessment based on structural and functional properties

Immunogenicity and safety of a recombinant adenovirus type-5-vectored 1745 COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, doubleblind, placebo-controlled, phase 2 trial

Complement regulators and inhibitory proteins